CHICAGO — Neelima Denduluri, MD, breast medical oncologist with Virginia Cancer Specialists and associate chair of breast cancer research with U.S. Oncology Network, spoke with HemOnc Today about exciting breast cancer research presented at ASCO Annual Meeting.
“There were a lot of exciting studies presented spanning the whole spectrum of cancer care, including survivorship and treatment of late-stage disease,” Denduluri told HemOnc Today.
Denduluri discussed a study presented by Matteo Lambertini, MD, that showed pregnancy after invasive early breast cancer appeared safe among women with BRCA mutations.
She addressed the impact of the MONALEESA-7 study, which showed premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer derived a significant OS benefit from the addition of ribociclib (Kisqali, Novartis) to endocrine therapy.
She also spoke about the expanding armamentarium of HER2-targeted therapies. – by Mark Leiser